Phase 4Completed

Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine Adsorbed

A Randomized, Open-label Study to Evaluate the Immunogenicity of Anthrax Vaccine Adsorbed Alone or Concomitantly With Raxibacumab (GSK3068483)

Sponsor
Emergent BioSolutions (Industry)
Enrollment
573 enrolled
Conditions
Infections, Bacterial
Interventions
AVA; Raxibacumab; Diphenhydramine
Ages
adults, older adults
Registry
NCT02339155

Full record on ClinicalTrials.gov

From the registry

This study, as a post-marketing commitment to the Food and Drug Administration, is designed to detect the effect of raxibacumab on anthrax vaccine adsorbed (AVA) immunogenicity in a healthy volunteer population. This is a randomized, open-label, parallel group, two arm study to compare the immunogenicity of AVA at 4 weeks after the first AVA dose, when AVA is administered alone or concomitantly with raxibacumab. The study is planned to enroll approximately 30 to 534 subjects in up to 3 cohorts. The total duration of the study will be approximately 26 weeks. The dates reflect cohort 1.

Primary outcomes

  • Ratio of Geometric Mean Concentrations (GMC) of Anti-protective Antigen (PA) Antibody (Ab) at 4 Weeks (Day 29) After the First AVA Dose (Prior to the Third AVA Dose), Between the AVA Alone and the AVA With Raxibacumab Treatment Groups

History

  1. Last registry update

  2. Results first posted

  3. Study completion

  4. Primary completion

  5. Started

  6. Registered